Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures

Background Insulin-like growth factor 1 receptor (IGF1R) targeted therapies have resulted in responses in a small number of patients with advanced metastatic Ewing's sarcoma. We performed morphoproteomic profiling to better understand response/resistance mechanisms of Ewing's sarcoma to IGF1R inhibitor-based therapy. Methodology/Principal Findings This pilot study assessed two patients with advanced Ewing's sarcoma treated with IGF1R antibody alone followed by combined IGF1R inhibitor plus mammalian target of rapamycin (mTOR) inhibitor treatment once resistance to single-agent IGF1R inhibitor developed. Immunohistochemical probes were applied to detect p-mTOR (Ser2448), p-Akt (Ser473), p-ERK1/2 (Thr202/Tyr204), nestin, and p-STAT3 (Tyr 705) in the original and recurrent tumor. The initial remarkable radiographic responses to IGF1R-antibody therapy was followed by resistance and then response to combined IGF1R plus mTOR inhibitor therapy in both patients, and then resistance to the combination regimen in one patient. In patient 1, upregulation of p-Akt and p-mTOR in the tumor that relapsed after initial response to IGF1R antibody might explain the resistance that developed, and the subsequent response to combined IGF1R plus mTOR inhibitor therapy. In patient 2, upregulation of mTOR was seen in the primary tumor, perhaps explaining the initial response to the IGF1R and mTOR inhibitor combination, while the resistant tumor that emerged showed activation of the ERK pathway as well. Conclusion/Significance Morphoproteomic analysis revealed that the mTOR pathway was activated in these two patients with advanced Ewing's sarcoma who showed response to combined IGF1R and mTOR inhibition, and the ERK pathway in the patient in whom resistance to this combination emerged. Our pilot results suggests that morphoproteomic assessment of signaling pathway activation in Ewing's sarcoma merits further investigation as a guide to understanding response and resistance signatures.

[1]  J. Ludwig.  Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future , 2008, Current opinion in oncology.

[2]  Razelle Kurzrock,et al.  Combining targeted therapies: practical issues to consider at the bench and bedside. , 2010, The oncologist.

[3]  D. Ludwig,et al.  IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor , 2007, Clinical Cancer Research.

[4]  S. Altekruse,et al.  Outcomes for children and adolescents with cancer: challenges for the twenty-first century. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Margit Rosner,et al.  Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. , 2008, Human molecular genetics.

[6]  Robin L. Jones,et al.  Biological Rationale and Current Clinical Experience With Anti-Insulin-Like Growth Factor 1 Receptor Monoclonal Antibodies in Treating Sarcoma: Twenty Years From the Bench to the Bedside , 2010, Cancer journal.

[7]  A. Tolcher,et al.  Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Schuetze,et al.  Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. , 2010, The Lancet. Oncology.

[9]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[10]  Stephen L. Abrams,et al.  Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells , 2006, Leukemia.

[11]  V. Subbiah,et al.  Targeted Therapy of Ewing's Sarcoma , 2010, Sarcoma.

[12]  Robert E. Brown,et al.  Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in Ewing family of tumors. , 2009, Annals of clinical and laboratory science.

[13]  Robert E. Brown,et al.  Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma. , 2011, International journal of clinical and experimental pathology.

[14]  V. Notario,et al.  Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation , 2003, Oncogene.

[15]  R. Kurzrock,et al.  Chemotherapy resistance and retreatment: a dogma revisited. , 2010, Clinical colorectal cancer.

[16]  O. Delattre,et al.  EWS/FLI-1 Silencing and Gene Profiling of Ewing Cells Reveal Downstream Oncogenic Pathways and a Crucial Role for Repression of Insulin-Like Growth Factor Binding Protein 3 , 2004, Molecular and Cellular Biology.

[17]  A. Lazar,et al.  Ewing’s Sarcoma: Standard and Experimental Treatment Options , 2009, Current treatment options in oncology.

[18]  W. R. Bishop,et al.  A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts , 2010, Molecular Cancer Therapeutics.

[19]  R. Maki.  Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[21]  A. Cabrera,et al.  EWING'S SARCOMA. , 1964, Surgery, gynecology & obstetrics.

[22]  Robert E. Brown,et al.  Morphogenomics and morphoproteomics: a role for anatomic pathology in personalized medicine. , 2009, Archives of pathology & laboratory medicine.

[23]  T. Hunter,et al.  Inappropriate Activation of the TSC/Rheb/mTOR/S6K Cassette Induces IRS1/2 Depletion, Insulin Resistance, and Cell Survival Deficiencies , 2004, Current Biology.

[24]  R. Kurzrock,et al.  A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors , 2010, Clinical Cancer Research.

[25]  Robert E. Brown,et al.  Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients , 2005, Expert review of proteomics.

[26]  R. Kurzrock,et al.  Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials , 2008, Molecular Cancer Therapeutics.